Skip to main content

Specialty Pharmacy

  • Radicava becomes first FDA-approved ALS drug in many years

    WASHINGTON — The Food and Drug Administration approved Mitsubishi Tanabe Pharma America’s Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis, commonly referred to as Lou Gehrig’s disease.

  • WHO to launch biosimilar prequalifying pilot project

    GENEVA — The World Health Organization will launch a pilot project for prequalifying biosimilar medicines this year, “a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries,” the organization stated.

  • Biohaven’s shares now listed on NYSE

    NEW HAVEN, Conn. — Biohaven Pharmaceutical Holding Co. commenced an IPO of 9.9 million common shares at an initial public offering price of $17 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 1,485,000 common shares at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the New York Stock Exchange on May 4 under the ticker symbol “BHVN.”

  • Fred’s reports total sales of $159.1M for the month of April

    MEMPHIS, Tenn. — Fred’s Pharmacy reported total sales for April decreased 3% year-over-year to $159.1 million compared to $163.9 million in April 2016. However, total comparable-store sales for the month increased 1.2% compared with a 0.3% increase in comparable sales in the prior year period.

  • AmerisourceBergen inks new 5-year supply deal with Express Scripts

    VALLEY FORGE, Pa. — AmerisourceBergen has signed a new five-year pharmaceutical supply agreement with Express Scripts. The companies on Monday announced that AmerisourceBergen would be supplying pharmaceuticals to Express Scripts through Sept. 30, 2022. The previous agreement, which began in 20212, was set to expire in September.

  • Stivarga receives expanded approval to include hepatocellular carcinoma

    WASHINGTON — The Food and Drug Administration on Thursday expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. The drug, manufactured by Bayer HealthCare Pharmaceuticals, is the first FDA-approved treatment for a liver cancer in almost a decade.
     

  • FDA approves first drug for specific form of Batten disease

    WASHINGTON — The Food and Drug Administration on Thursday approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. BioMarin Pharmaceuticals’ Brineura is the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency.

  • Diplomat to dispense Zejula

    FLINT, Mich. — Diplomat Pharmacy on Wednesday announced that it had been selected to the specialty pharmacy panel dispensing Zejula (niraparib). The drug is a once-daily oral maintenance treatment indicated to treat women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
     
    Zejula is the first poly ADP-ribose polymerase inhibitor approved by the Food and Drug Administration that doesn’t require BRCA mutation or other biomarker testing, Diplomat said.
     
X
This ad will auto-close in 10 seconds